Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

With Genetic Testing Results, More May Be Better

Kathryn Doyle  |  January 26, 2016

(Reuters Health)—When people undergo genetic testing to find out whether they’re at risk for a specific disease, doctors often wonder how much information to give them. What if the genetic testing results reveal a risk for a disease the patient hadn’t been wondering about?

Geneticists are “grappling with what to do with all the information that could be disclosed, but wasn’t why the study was ordered in the first place,” Kurt D. Christensen of Brigham and Women’s Hospital in Boston told Reuters Health.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Though in theory, giving people more risk information than they were expecting might increase anxiety or depression, that didn’t turn out to be the case in a study Christensen recently led.

He and his colleagues studied a group of volunteers who were having tests to see if they’re genetically at risk for Alzheimer’s disease. It turned out these people weren’t more distressed when they received additional results about their risk for coronary artery disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In some cases, those who got extra information were actually less distressed one year later.

“It was the opposite of what we were expecting,” Christensen said in a phone interview.

That might be because patients can do little about their risk for Alzheimer’s disease, but lifestyle changes can help prevent future coronary artery disease, the authors wrote in the Annals of Internal Medicine on Jan. 26.

These results might help researchers and doctors decide how much information to give patients based on genetic testing results, Christensen said.

The researchers included 257 adults without symptoms, more than half of who had a close relative with Alzheimer’s disease, to be tested for a variant of the apolipoprotein E (APOE) gene, which has a strong association with Alzheimer’s disease risk.

All participants received information about their APOE genotype, cumulative lifetime risk of Alzheimer’s—which ranged from 6% to 73%—and risk up to age 85. Half the group was also told that the same gene variant that increases Alzheimer’s risk may also increase coronary artery disease risk, and that this risk can be reduced by quitting smoking, having a healthy diet, losing weight and treating high cholesterol.

The researchers assessed each subject’s anxiety, depression, distress and health behavior changes like diet and exercise activities at six weeks, six months and 12 months after they received the genetic results.

At the one-year point, anxiety and depression scores were similar in both groups. Among those who were carriers of the high-risk APOE allele, those who were also told about their coronary artery disease risk had lower distress levels and more healthy behavior changes than those who only got Alzheimer’s information.

Page: 1 2 | Single Page
Share: 

Filed under:Practice SupportTechnology Tagged with:Alzheimer's DiseaseGenetic researchgenetic riskgenetic testgeneticsTesting

Related Articles

    7 Tools to Identify Depression

    August 1, 2014

    Why screening for depressive symptoms in patients with arthritis is needed

    Exploring Kawasaki Disease

    April 2, 2014

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    Depression in Rheumatoid Arthritis

    November 1, 2012

    Examining the psychological and health-related comorbidities of rheumatoid arthritis patients with depression

    Anxiety Is an Independent Risk Factor for Bone Fractures

    November 18, 2018

    Higher anxiety levels in postmenopausal women may put them at increased risk of fracture and should be considered when assessing a woman’s risk of osteoporosis as well. This is the conclusion of a study recently published in the journal Menopause that looked at the role of anxiety in bone health.1 Specifically, the study examined the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences